In Northern Ireland, as elsewhere, hypertension remains a leading cause of morbidity and mortality. Controversy has existed for many years regarding the optimal pharmacological agents for the management of this condition. However, in the UK, both historical and more recent data show that in clinical practice beta-blockers and diuretics are the most commonly prescribed first-line agents for blood pressure (BP) management.
1,2 This pattern of prescribing will have been driven by issues such as cost and availability. In addition, a variety of guidelines from bodies such as British Hypertension Society (BHS), National Institute for Clinical Excellence (NICE) and the European Society of Hypertension will have influenced many doctors. However, these separate guidelines have been seen by some as incongruous, leading to confusion and further controversy.
In 2006, BHS and NICE jointly issued new guidelines for the management of hypertension. 3 These advocate the use of either an angiotensinconverting enzyme inhibitor or angiotensin receptor blocker (ACE/ARB) as first-line treatment in young (o55 years), non-black patients with essential hypertension, whereas black patients and the elderly should receive calcium channel blockers (CCB) or diuretics. In view of these recent guidelines, we performed a survey of the prescribing practices for the treatment of hypertension among senior physicians within Northern Ireland. In May/ June 2006, all 1082 general practitioners (GPs) registered within Northern Ireland, and 159 senior hospital physicians were invited to complete an anonymous postal survey. The doctors were given three theoretical scenarios and asked to choose which drug class would be their initial treatment of choice. Doctors were instructed to assume that the patients had new onset essential hypertension, which was sustained despite lifestyle modifications. The three scenarios were Our aim was to determine whether the initial pharmacological treatments varied by the specialty of the prescriber, and to what degree current guidelines are adhered to.
Within Northern Ireland, patients with problematic hypertension in primary care are referred mainly, but not exclusively, to cardiology outpatients. Thus, on analysis, the doctors were subdivided into GPs, cardiologists and other hospital physicians.
Five hundred and forty (49.9%) GPs and 98 (61.6%) senior hospital physicians responded to the postal survey, including 25 cardiologists. The majority of doctors gave single drug class preferences although a minority of responders preferred dual therapy or had no preference between two or three drug classes. In these instances it was assumed that the doctor considered both/ all medications chosen to be appropriate initial treatments.
The results are summarized in Figure 1 . More detailed results are available in Supplementary  Tables 1-7 . Scenario 1: The favoured drug class in all specialties was ACE/ARB with 92.0% of cardiologists (23/25, P ¼ 0.001) selecting this drug class compared with 58.9% of GPs (318/540, P ¼ 0.003) and 64.4% of other hospital physicians (47/73, P ¼ 0.079). This preference for ACE/ARB was present across all medical specialties. There was a slight, but significant difference between cardiologists, hospital physicians and GP (92 vs 64.4 vs 58.9% Pearson w 2 P ¼ 0.003) in that cardiologists were less likely to deviate from ACE/ARB and prescribe other drug classes than other groups. A sizable minority of GPs and other hospital physicians identified other agents, specifically diuretics, beta-blockers and CCB.
No hospital physicians would withhold medications in this scenario, although 6/540 (1.1%) GPs would not initiate drug therapy.
Scenario 2: ACE/ARB therapy was the clear preference among all specialties in this scenario with 91.5% of GPs (494/540, Po0.001), all cardiologists (25/25, Po0.001) and all hospital physicians (72/72, Po0.001) identifying this drug class as preferred first-line therapy. A subtle difference was present on detailed analysis with GPs the only subgroup to show any tendency to prefer drugs other than ACE/ ARB (100 vs 100 vs 91.5% Fishers Exact test P ¼ 0.014).
There were no instances of any doctors surveyed choosing not to initiate drug therapy in this scenario.
Scenario 3:
The salient feature was preponderance for CCB or diuretics in this patient group with 84% of cardiologists (21/25, P ¼ 0.01), 88.1% of GP (476/ 540, Po0.001) and 86.1% of other hospital physicians (62/72, Po0.001) identifying one or both of these agents as a preferred drug class. Again this pattern was observed among the different medical specialties. The pattern of prescribing was similar across the subgroups (cardiology 84% vs GP 88.1% vs other hospital physicians 86.1% Fishers Exact test P ¼ NS). A small minority of GPs (0.6%) and other hospital physicians (4.2%) would not prescribe medication in this instance.
This survey demonstrates that in clinical practice within Northern Ireland, marked similarities exist in prescribing patterns among GPs, cardiologists and other hospital physicians for the initial treatment of patients with essential hypertension. Furthermore, the prescribing policies closely mirror existing advice.
The first scenario describes the young, uncomplicated hypertensive patient. No clinical outcome trial has been carried out which examines the use of particular antihypertensive agents in this cohort. This may explain the larger spread, of preferences observed in this setting when compared with the other scenarios. Overall, however, Northern Ireland physicians favour ACE/ARB over all other options and this pattern of prescribing appears justified. It is known that younger non-black patients have a tendency towards renin-dependent hypertension and are therefore more likely to respond to those drugs that manipulate the renin-angiotensin system (that is ACE/ARB/beta-blockers). Recently, however, beta-blockers have been identified as being less effective in preventing stroke than other agents. 4 Furthermore, recent studies have highlighted the increased risk of developing type II diabetes with prolonged use of this drug class. 5, 6 Thus, it appears that ACE/ARB can be considered the optimal drug class in this patient group and this is reflected in the prescribing practices. The preference among some GPs and hospital physicians to prefer drugs other than ACE/ARB may result from the lack of randomized outcome trials in this patient group and perhaps highlights the need for such a study to be undertaken.
The second scenario describes the 'high-risk' patient who, as well as hypertension, has a number of other risk factors for developing cardiovascular disease. This patient cohort has been intensively studied with large randomized trials providing a solid evidence base for treatment policies. Perhaps controversially, our study demonstrates that Northern Ireland physicians overwhelmingly prefer to prescribe ACE/ARB in this patient group. It can be argued that this in keeping with the available evidence with important trials such as HOPE, ASCOT and LIFE promoting the prescription of ACE/ARB in this scenario. 5, 7, 8 The controversy lies in that BHS/NICE guidelines advise the prescription Figure 1 Proportion of physicians who identified each drug class in scenario (1) a 42-year-old white man with no past medical history and blood pressure (BP) 165/95 mm Hg (top graph); scenario (2) a 65-year-old white, obese, type II diabetic patient with hypercholesterolaemia and BP 165/90 mm Hg (middle graph); scenario (3) a 72-year-old white woman with no past medical history and BP 175/80 mm Hg (bottom graph). *Physicians may have chosen more than one drug class. ACE/ ARB, angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker; ALPHA-B, alpha blocker; BB, beta-blocker; CCB, calcium channel blocker; DIUR, diuretic; NONE, drug treatment felt inappropriate. of CCB or diuretics for patients in this age group. This finding suggests that Northern Ireland physicians are influenced more by the 'high-risk' nature of the patient as opposed to the chronological age. This was seen most clearly among hospital physicians who were less likely to deviate from the prescription of ACE/ARB when compared to their GP colleagues.
Scenario 3 describes an older lady with isolated systolic hypertension. It is now accepted that treatment of hypertension in this patient group is clearly justified. It was thus surprising that our survey revealed a small minority of GPs and hospital physicians who remain reluctant to initiate medication in the elderly hypertensive. There were no cardiologists and only 1 out of 18 elderly care physicians who would withhold treatment in this scenario, which may reflect a more interventional attitude among these doctor groups.
The majority of all physicians favour diuretics or CCB as first line for the elderly patient with a new diagnosis of hypertension and this complements the current evidence base. Support for diuretics comes from trials such as the Systolic Hypertension in the Elderly Program (SHEP) and Medical Research Council (MRC), which highlighted the benefit of diuretic therapy over placebo and beta-blocker, respectively. 9, 10 Similarly, while the Hypertension Optimal Treatment (HOT) trial underlined the role of long acting CCBs in the treatment of hypertension, Syst-Eur and Nordic Diltiazem (NORDIL) study highlighted their efficacy in the elderly. 11, 12 Historically, beta-blockers have been one of the most widely used drug classes for use in treating hypertension. Our survey demonstrates a clear move away from these as first-line therapy in the management of hypertension. It is stressed, however, that they remain part of the updated BHS/NICE algorithm and continue to have a role in the treatment of hypertensive patients, particularly those who have co-existent ischaemic heart disease (IHD), congestive cardiac failure (CCF) or cardiac arrhythmia.
In conclusion, this observational study demonstrates marked similarities in prescribing patterns between primary and secondary care within Northern Ireland, with only subtle differences observed on detailed analysis. Furthermore, the prescribing appears evidence based, demonstrating the value of education, coupled with simple and transparent guidelines, ensuring optimal initial treatment of patients with hypertension within Northern Ireland. 
